Mitchell H. Grayson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mitchell H. Grayson has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
Michelle Rohlfing
Division of Allergy and Immunology, Department of Pediatrics, Nationwide Children’s Hospital - The Ohio State University College of Medicine, Columbus, USA
10 shared publications- Syed-Rehan A. Hussain
Division of Allergy & Immunology, Center for Clinical and Translational, Abigail Wexner Research Institute, Nationwide Children's Hospital, USA
8 shared publications Dorothy S. Cheung
Division of Allergy and Immunology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wis
7 shared publications- Joel M. Gelfand
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Center for Clinical Sciences in Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
7 shared publications - Jonathan Ian Silverberg
Department of Dermatology, The George Washington University School of Medicine and Health Sciences , Washington, DC
7 shared publications - Peck Y. Ong
Division of Clinical Immunology and Allergy, Children's Hospital Los Angeles; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California
7 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 7, 1952677
Are we there yet? understanding interactions between respiratory viral infections, atopy, and the microbiome
Atopic disease has become an increasingly prevalent condition worldwide and a significant health concern. Similarly, due to concerns about morbidity associated with respiratory viral illness in early childhood, there has been increased exploration of the relationship between atopy and viral illnesses. Historically, studies have focused on early-life respiratory infections driving the development of atopy or post-viral airway disease, with respiratory syncytial virus (RSV) infection driving post-viral disease in those without atopy, while human rhinovirus (hRV) leading to asthma in those with pre-existing atopy. The impact of atopy on the antiviral immune response remains debated, with some studies suggesting it provides a protective role, while others suggest it impairs the immune response. Beyond the respiratory tract, the gut microbiome increasingly is recognized as a potential modulator of both local and distant immune responses, a relationship associated with lung function termed the gut-lung axis. As we continue to elucidate the biochemical mechanisms underlying these pathways in mouse models, it will be important to identify analogous human pathways. This review explores what is currently known about the relationship between atopy and respiratory viral infections focusing on knowledge about how viral infections drive atopy and, reciprocally, how atopy modulates respiratory viral induced disease. Moreover, we review published information on analogous human pathways. Utilizing this information will help us with better disease management and potential development of targeted therapeutics.
- 18 September 2026
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 7, 1952677
Open AccessAre we there yet? understanding interactions between respiratory viral infections, atopy, and the microbiome
Atopic disease has become an increasingly prevalent condition worldwide and a significant health concern. Similarly, due to concerns about morbidity associated with respiratory viral illness in early childhood, there has been increased exploration of the relationship between atopy and viral illnesses. Historically, studies have focused on early-life respiratory infections driving the development of atopy or post-viral airway disease, with respiratory syncytial virus (RSV) infection driving post-viral disease in those without atopy, while human rhinovirus (hRV) leading to asthma in those with pre-existing atopy. The impact of atopy on the antiviral immune response remains debated, with some studies suggesting it provides a protective role, while others suggest it impairs the immune response. Beyond the respiratory tract, the gut microbiome increasingly is recognized as a potential modulator of both local and distant immune responses, a relationship associated with lung function termed the gut-lung axis. As we continue to elucidate the biochemical mechanisms underlying these pathways in mouse models, it will be important to identify analogous human pathways. This review explores what is currently known about the relationship between atopy and respiratory viral infections focusing on knowledge about how viral infections drive atopy and, reciprocally, how atopy modulates respiratory viral induced disease. Moreover, we review published information on analogous human pathways. Utilizing this information will help us with better disease management and potential development of targeted therapeutics.
- 1 September 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 137 (3) , 269
Introducing the distinguished authors of 2026
- 1 September 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 137 (3) , 269
Introducing the distinguished authors of 2026
- Open Access
- 10 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Single-cell RNA sequencing of hematopoietic and non-hematopoietic cells defines a distinct signature in atopic and NRG1 mouse lung
Respiratory viral infections cause significant mortality. Pre-existing atopy has demonstrated protection from virus-induced death. Atopic mice with house dust mite (HDM) extract survive normally lethal parainfluenza (Sendai virus, SeV) and influenza A (IAV) infection. Neuregulin-1 (NRG1), markedly elevated in airways of atopic mice, has been shown to significantly attenuate mortality to SeV and IAV in non-atopic mice. Hypothesizing that atopy and NRG1 mediate protection from death through similar mechanisms, we anazlyed single-cell RNA sequencing data from CD45+ (hematopoietic) and CD45- (structural) lung cells prior to infection. Both treatments reduced alveolar macrophages, lymphatic endothelial cells, airway smooth muscle cells, and pericytes, while increasing alveolar type 2 cells. However, atopy led to increased fibroblasts with reduced club cells compared to NRG1 treatment. Further, in the hematopoietic cell compartment, atopy drove an increase in more inflammatory cells than NRG1 and associated with significant upregulation of immune cell signaling pathways, something not seen with NRG1 administration. Moreover, NRG1 knockdown did not reverse the protection from virus-induced death in mice with pre-existing atopy. Taken together, these data strongly suggest that atopy and NRG1 mediate increased survival from a respiratory viral infection through disparate mechanisms.
- 10 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessSingle-cell RNA sequencing of hematopoietic and non-hematopoietic cells defines a distinct signature in atopic and NRG1 mouse lung
Respiratory viral infections cause significant mortality. Pre-existing atopy has demonstrated protection from virus-induced death. Atopic mice with house dust mite (HDM) extract survive normally lethal parainfluenza (Sendai virus, SeV) and influenza A (IAV) infection. Neuregulin-1 (NRG1), markedly elevated in airways of atopic mice, has been shown to significantly attenuate mortality to SeV and IAV in non-atopic mice. Hypothesizing that atopy and NRG1 mediate protection from death through similar mechanisms, we anazlyed single-cell RNA sequencing data from CD45+ (hematopoietic) and CD45- (structural) lung cells prior to infection. Both treatments reduced alveolar macrophages, lymphatic endothelial cells, airway smooth muscle cells, and pericytes, while increasing alveolar type 2 cells. However, atopy led to increased fibroblasts with reduced club cells compared to NRG1 treatment. Further, in the hematopoietic cell compartment, atopy drove an increase in more inflammatory cells than NRG1 and associated with significant upregulation of immune cell signaling pathways, something not seen with NRG1 administration. Moreover, NRG1 knockdown did not reverse the protection from virus-induced death in mice with pre-existing atopy. Taken together, these data strongly suggest that atopy and NRG1 mediate increased survival from a respiratory viral infection through disparate mechanisms.
- Open Access
- 30 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (18)
Gingipain proteases from the bacterium Porphyromonas gingivalis confer protection against airway viral infection
Physical interactions with bacterial colonizers at mucosal barrier surfaces can have beneficial or detrimental effects on viral infectivity and transmission. The oropharyngeal mucosal surface is a major portal of entry for many pathogenic respiratory viruses, such as respiratory syncytial virus (RSV), and also harbors a rich and diverse microbiome. Whether oropharyngeal bacteria directly or indirectly influence host susceptibility to respiratory viruses remains unknown. Here, we show that Porphyromonas gingivalis , an oral pathobiont, potently and uniquely suppresses airway epithelial antiviral immunity by degrading interferons (IFNs) and transcriptionally repressing multiple IFN-stimulated genes (ISGs), which are essential for providing resistance to viral infection. Despite inducing a state of IFN hyporesponsiveness, we found that P. gingivalis counterintuitively protected against severe infection by RSV and the closely related murine-specific Sendai virus (SeV) in two independent models: human airway bronchial epithelial transwell cultures and airway infection in mice. This protection was conferred by the activity of P. gingivalis cysteine proteases (gingipains) that cleaved envelope glycoproteins on RSV and SeV, thereby impairing their infectious capacity. Thus, our data show a nuanced role for P. gingivalis in modulating host susceptibility to viral infection. While P. gingivalis can significantly inhibit host IFN responses, its proteases preemptively reduce viral infectious capacity, protecting the host from severe damage associated with respiratory infections.
- 30 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (18)
Open AccessGingipain proteases from the bacterium Porphyromonas gingivalis confer protection against airway viral infection
Physical interactions with bacterial colonizers at mucosal barrier surfaces can have beneficial or detrimental effects on viral infectivity and transmission. The oropharyngeal mucosal surface is a major portal of entry for many pathogenic respiratory viruses, such as respiratory syncytial virus (RSV), and also harbors a rich and diverse microbiome. Whether oropharyngeal bacteria directly or indirectly influence host susceptibility to respiratory viruses remains unknown. Here, we show that Porphyromonas gingivalis , an oral pathobiont, potently and uniquely suppresses airway epithelial antiviral immunity by degrading interferons (IFNs) and transcriptionally repressing multiple IFN-stimulated genes (ISGs), which are essential for providing resistance to viral infection. Despite inducing a state of IFN hyporesponsiveness, we found that P. gingivalis counterintuitively protected against severe infection by RSV and the closely related murine-specific Sendai virus (SeV) in two independent models: human airway bronchial epithelial transwell cultures and airway infection in mice. This protection was conferred by the activity of P. gingivalis cysteine proteases (gingipains) that cleaved envelope glycoproteins on RSV and SeV, thereby impairing their infectious capacity. Thus, our data show a nuanced role for P. gingivalis in modulating host susceptibility to viral infection. While P. gingivalis can significantly inhibit host IFN responses, its proteases preemptively reduce viral infectious capacity, protecting the host from severe damage associated with respiratory infections.
- 3 April 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 136 (4) , 371
Everything immunodeficiency
- 3 April 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 136 (4) , 371
Everything immunodeficiency
- 2 March 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 136 (3) , 245
Crystal ball: Predictions for urticaria treatment and lung function trajectories
- 2 March 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 136 (3) , 245
Crystal ball: Predictions for urticaria treatment and lung function trajectories
- 2 March 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 136 (3) , 248
Open access is essential for research funded by the National Institutes of Health (NIH)
- 2 March 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 136 (3) , 248
Open access is essential for research funded by the National Institutes of Health (NIH)
- 15 November 2025
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 135 (6) , 614-615
2025 American College of Allergy, Asthma and Immunology Annals fellow-in-training award winners
- 15 November 2025
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 135 (6) , 614-615
2025 American College of Allergy, Asthma and Immunology Annals fellow-in-training award winners
- 1 September 2025
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 135 (3) , 243-244
On a wheeze and a prayer
- 1 September 2025
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 135 (3) , 243-244
On a wheeze and a prayer
- 7 May 2025
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 134 (5) , 499
10 ways to improve …
- 7 May 2025
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 134 (5) , 499
10 ways to improve …